Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 0.484 -0.0161 (-3.22%) Market Cap: 33.08 Mil Enterprise Value: 34.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q4 2019 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Feb 18, 2020 / 01:00PM GMT
Release Date Price: $6.33 (+22.67%)
Operator

Greetings and welcome to the BrainStorm Cell Therapeutics fourth quarter 2019 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. It is my pleasure to introduce your host, Sean Leous with ICR. Please go ahead.

Sean Leous
ICR,Inc. - SVP

Thank you for joining the BrainStorm Cell Therapeutics fourth quarter and full year 2019 financial results conference.

Before we begin the prepared remarks, we would like to remind listeners that this conference contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics, Inc., Nasdaq: BCLI, and it's potential future business operations and performance statements regarding the market potential for treatment of neurodegenerative disorders such as ALS and MS, sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our NurOwn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot